I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.043 SGD
-10.42%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one 42C stock under the Base Case scenario is 0.033 SGD. Compared to the current market price of 0.043 SGD, IX Biopharma Ltd is Overvalued by 24%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
42C
Relative Value
Base Case
0.033
SGD
Overvaluation 24%
I
Valuation Multiples
Multiples Across Competitors
42C Competitors Multiples
IX Biopharma Ltd Competitors
IX Biopharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| SG |
I
|
IX Biopharma Ltd
SGX:42C
|
33m SGD | 5.5 | -3.4 | -5.2 | -4.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
739.8B USD | 20.6 | 120.5 | 59 | 67.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 16.2 | 44.3 | 33 | 36.2 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
358.6B USD | 4.2 | 9.3 | 11.5 | 15 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
328.3B USD | 5.3 | 142.4 | 35.5 | 57.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
190.1B GBP | 5 | 37.5 | 174.5 | 278.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
177.1B CHF | 3 | 15.4 | 8.8 | 10.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
177.1B CHF | 3.3 | 11.1 | 8.5 | 12.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.9B USD | 2.9 | -514.2 | 12.8 | 20.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
